NCT04000971

Brief Summary

Stroke is the 5th leading cause of death and the leading cause of adult disability in the United States (US). Stroke is a complex disease with multiple interacting risk factors (including genetic, high blood pressure and cholesterol, and lifestyle factors like smoking, diet, and exercise) that lead to initial and recurrent stroke. Up to 90% of stroke survivors have some functional deficit that impacts both physical and mental health.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,196

participants targeted

Target at P75+ for not_applicable stroke

Timeline
Completed

Started Feb 2020

Longer than P75 for not_applicable stroke

Geographic Reach
1 country

21 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 25, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 27, 2019

Completed
8 months until next milestone

Study Start

First participant enrolled

February 25, 2020

Completed
4.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2024

Completed
1.6 years until next milestone

Results Posted

Study results publicly available

May 15, 2026

Completed
Last Updated

May 15, 2026

Status Verified

April 1, 2026

Enrollment Period

4.6 years

First QC Date

June 25, 2019

Results QC Date

October 29, 2025

Last Update Submit

April 23, 2026

Conditions

Keywords

Technology-enabledEngagement, caregiverTeam-basedIntegrated Care

Outcome Measures

Primary Outcomes (2)

  • Stroke Impact Scale (SIS) at 12-months Post-discharge

    59-item questionnaire to assess aspects of patient quality of life following stroke; includes 8 dimensions assessed on a 5-point Likert scale that are summed by domain. Scores range from 0-100, with higher scores indicating less difficulty.

    12 months post-stroke

  • Modified Rankin Scale at 12 Months Post-stroke

    The Modified Rankin Score (mRS) is a widely used scale to measure the degree of disability or dependence in daily activities of individuals who have suffered a stroke. Scores were categorized as 0-2 or \>2. Overview of the Modified Rankin Scale * 0: No symptoms at all * 1: No significant disability; able to carry out all usual activities * 2: Slight disability; unable to carry out all previous activities but able to look after own affairs without assistance * 3: Moderate disability; requiring some help, but able to walk unassisted * 4: Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance * 5: Severe disability; bedridden, incontinent, and requiring constant nursing care * 6: Dead

    12 months post-stroke

Secondary Outcomes (35)

  • Stroke Impact Scale (SIS) at 3-months Post-discharge

    3-months post-stroke

  • Stroke Impact Scale (SIS) at 6-months Post-discharge

    6-months post-discharge

  • Modified Rankin Scale (mRS) at 3-months Post-discharge

    3-months post-stroke

  • Modified Rankin Scale (mRS) at 6-months Post-discharge

    6-months post-discharge

  • Stroke Risk Factors - Blood Pressure Control (BP) at 3-months Post-discharge

    3-months post-discharge

  • +30 more secondary outcomes

Study Arms (2)

Integrated Stroke Practice Unit (ISPU)

ACTIVE COMPARATOR

ISPU personnel will continue with care provided under the Joint Commission-certified CSC/PSC design, including a 30-day clinic visit post-discharge. This will be supplemented by a more integrated model designed to increase coordination through team-based initiatives across the continuum of care for stroke - from acute and in-hospital care through 12 months post-discharge. Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, increase understanding, and build positive behavior change for patients and caregivers. Primary outcomes will be assessed by phone at 3, 6, and 12 months; secondary outcomes will be assessed at 3, 6, and 12 months.

Other: Integrated Stroke Practice Unit

Comprehensive or Primary Stroke Center (CSC/PSC)

ACTIVE COMPARATOR

CSC/PSC personnel will continue with care provided under the Joint Commission-certified CSC/PSC design, including a 30-day clinic visit post-discharge, follow-up clinic visits as recommended by their outpatient provider, and other clinic visits initiated by the patient when issues arise. Primary outcomes will be assessed by phone at 3, 6, and 12 months; secondary outcomes will be assessed at 3, 6, and 12 months.

Other: Comprehensive or Primary Stroke Center

Interventions

Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, and increase understanding and build positive behavior change for patients and caregivers. Primary and secondary outcomes will be assessed at 3, 6, and 12 months.

Also known as: ISPU
Integrated Stroke Practice Unit (ISPU)

Primary and secondary outcomes will be assessed at 3, 6, and 12 months.

Also known as: CSC/PSC
Comprehensive or Primary Stroke Center (CSC/PSC)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18+.
  • Clinical diagnosis of acute stroke with brain imaging compatible with intracerebral hemorrhage or ischemic stroke (including normal brain scan); see International Classification of Disease 10 (ICD 10) codes.
  • English or Spanish speaking subjects.
  • Patient admitted within 7 days of their index stroke event.
  • Patient is discharged alive and not to hospice care.
  • Patient living at discharge within the geography of recruitment for that C3FIT site.
  • Pre-morbid Modified Rankin Score (mRS) score of 0-1.
  • Patient and/or surrogate give consent to participate after an informed consent process.
  • Patients who go to rehabilitation inpatient therapy or other care facilities are eligible, as long as they reside in the geographic are of recruitment and do not go to hospice care.

You may not qualify if:

  • Clinical transient ischemic attack (TIA)38-41 is excluded even if there is a computerized tomography (CT) or magnetic resonance imaging (MRI) lesion corresponding to the clinical syndrome at presentation.
  • Already enrolled or planned enrollment in another clinical trial for which participation in C3FIT would be compromised with regard to follow-up assessment of outcomes or continuation in C3FIT.
  • Patients with a planned admission to hospice care prior to consent.
  • Patients not anticipated to survive for 1-year due to neurological or other medical status (i.e., advanced cancer, hospice care, heart disease, etc.).
  • Patients who in the opinion of the site investigator cannot be involved in follow up care.
  • Inability or unwillingness of subject or legal guardian/representative to understand and cooperate with study procedures or provide informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (21)

University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States

Location

Mayo Clinic Hospital

Phoenix, Arizona, 85054, United States

Location

Hartford Hospital

Hartford, Connecticut, 06102, United States

Location

Mayo Clinic

Jacksonville, Florida, 32224, United States

Location

Emory University/Grady Health

Atlanta, Georgia, 30303, United States

Location

Augusta University Medical Center

Augusta, Georgia, 30912, United States

Location

Northwestern University

Chicago, Illinois, 60611, United States

Location

University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

Location

University of Louisville Hospital

Louisville, Kentucky, 40202, United States

Location

Intermountain

Las Vegas, Nevada, 89128, United States

Location

University of New Mexico Health Sciences Center

Albuquerque, New Mexico, 87131, United States

Location

Ohio Health Riverside Methodist Hospital

Columbus, Ohio, 43214, United States

Location

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States

Location

Penn State

State College, Pennsylvania, 16802, United States

Location

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

Johnson City Medical Center at Ballad Health

Johnson City, Tennessee, 37604, United States

Location

Covenant Health Fort Sanders Regional Medical Center

Knoxville, Tennessee, 37916, United States

Location

Baptist Memorial Hospital

Memphis, Tennessee, 38120, United States

Location

Vanderbilt University Medical Center

Nashville, Tennessee, 37322, United States

Location

Doctors Hospital Renaissance

Edinburg, Texas, 78539, United States

Location

University of Wisconsin Madison

Madison, Wisconsin, 53705, United States

Location

Related Publications (1)

  • Commiskey P, Long DL, Howard VJ, Braunlin J, Howard G, Cochran D, Jackson B, Bell D, Hill D, Callahan AE, Gaines K. Design and methods of a cluster-randomized pragmatic trial of post-discharge stroke care. Contemp Clin Trials. 2025 Jun;153:107890. doi: 10.1016/j.cct.2025.107890. Epub 2025 Apr 4.

MeSH Terms

Conditions

StrokeIschemic StrokePatient ParticipationHemorrhagic Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesPatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Limitations and Caveats

C3FIT's "active control" group (where patients in the comparator group received (The Joint Commission (TJC)-prescribed treatments proven to substantially improve mortality/functional outcomes) may have made it difficult to show the benefit of ISPU+CSC management. C3FIT also planned to follow patients for 2-years, but coronavirus disease-2019 and other challenges shortened follow-up to only 1-year, which may not have been sufficient for the benefit to be experienced on the primary outcomes.

Results Point of Contact

Title
Dr. Kenneth Gaines
Organization
Vanderbilt University Medical Center

Study Officials

  • Kenneth Gaines, MD

    Vanderbilt University Medical Center

    PRINCIPAL INVESTIGATOR
  • Barry Jackson

    PRINCIPAL INVESTIGATOR
  • George Howard, DrPH

    University of Alabama at Birmingham

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Primary outcomes will be assessed by telephone at 3, 6, and 12 months by the University of Alabama at Birmingham (UAB)'s Survey Research Unit (SRU). Research staff at the SRU will be masked to treatment arm.
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Model Details: Pragmatic randomized trial of approximately 22 clinical sites in the United States; randomization is by clinical site.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, Neurology; Medical Director, Vanderbilt Teleneurology

Study Record Dates

First Submitted

June 25, 2019

First Posted

June 27, 2019

Study Start

February 25, 2020

Primary Completion

September 30, 2024

Study Completion

September 30, 2024

Last Updated

May 15, 2026

Results First Posted

May 15, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations